Physician profile
Singwu David Law
NPI 1760709265
$19,764.46
in general payments reported to CMS, 2019-2025
19 companies · $4,154 in 2025
The $4,154 reported for 2025 was more than what 92% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $1,480 · 2021: $2,337 · 2022: $2,506 · 2023: $3,560 · 2024: $4,334 · 2025: $4,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,047.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,672.17 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,449.29 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Glaxosmithkline, LLC. | $4,149.39 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Philips North America LLC | $1,404.18 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Genentech USA, INC. | $653.73 | 2019-2025 | Xolair |
| Electromed, INC. | $616.44 | 2019-2025 | Smartvest |
| Insmed, INC. | $475.52 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $300.98 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $238.09 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $202.79 | 2022 | |
| Amgen INC. | $184.79 | 2022-2025 | Tezspire, Krystexxa |
| Esperion Therapeutics, INC. | $133.70 | 2022 | |
| Genzyme Corporation | $103.96 | 2024-2025 | |
| Lilly USA, LLC | $61.10 | 2025 | Zepbound, Mounjaro |
| Mylan Specialty L.P. | $34.75 | 2023 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $24.00 | 2023 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $22.50 | 2019 | |
| Circassia INC. | $19.58 | 2019 | |
| Optinose US, INC. | $17.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Singwu Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.